Physician profile
Sandra C Beta
NPI 1265980932
$2,513.39
in general payments reported to CMS, 2019-2025
19 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $562 · 2022: $124 · 2023: $825 · 2024: $531 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,826.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $977.49 | 2021-2024 | Enhertu, Calquence, Imfinzi |
| Abbott Laboratories | $306.64 | 2021-2023 | Proclaim, Eterna |
| E.R. Squibb & Sons, L.L.C. | $197.67 | 2023-2024 | Reblozyl |
| Daiichi Sankyo INC. | $150.79 | 2021-2023 | Enhertu |
| Madrigal Pharmaceuticals | $141.60 | 2025 | Rezdiffra |
| Legend Biotech USA INC. | $132.56 | 2025 | Carvykti |
| Pharmaessentia USA Corporation | $100.00 | 2025 | Besremi |
| Amgen INC. | $91.58 | 2024 | |
| Syndax Pharmaceuticals, INC. | $78.48 | 2025 | Revuforj |
| Janssen Biotech, INC. | $73.30 | 2022 | |
| Genentech USA, INC. | $71.28 | 2021 | |
| Seagen INC. | $48.17 | 2022-2023 | Tivdak |
| Merck Sharp & Dohme LLC | $28.97 | 2021 | |
| Blueprint Medicines Corporation | $24.63 | 2023 | Ayvakit |
| Eisai INC. | $24.08 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $17.56 | 2025 | |
| Relievant Medsystems, INC. | $17.11 | 2022 | |
| Servier Pharmaceuticals LLC | $15.88 | 2023 | |
| Pfizer INC. | $15.60 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Beta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.